AZD-3229

N/A

Report date: 2026/04/25 20:00:23
NME

Base Information

Drug NameAZD-3229
Drug Alias NameNB-003NB003AZD-3229AZD3229
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionStem cell growth factor receptor inhibitorsPlatelet-derived growth factor receptor alpha inhibitors
TargetsStem cell growth factor receptorPlatelet-derived growth factor receptor alpha
Therapy Area/IndicationsSolid tumoursGastrointestinal Stromal TumorsInfluenza B virus infection
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomFrance +[6] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAstrazeneca Turkey
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAstrazeneca TurkeyBrightgene Bio-Medical Technology Co LtdNingbo Tai Kang Medical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursGastrointestinal Stromal TumorsInfluenza B virus infection
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A